Angiogenesis is a primary requisite for progression of malignant solid tumours (Folkman, 1992) . During tumour growth and metastasis, endothelial cells proliferate, degrade the surrounding basement membrane and migrate into the stroma. Finally, they differentiate, giving rise to new vessels (Blood and Zetter, 1990) which are crucial for nutrient delivery to tumours.
The interaction of endothelial cells with their microenvironment, especially with extracellular matrix components, plays an essential role during the angiogenic process (Ingber, 1992) . It has been shown that basement membrane proteins, such as laminin (Grant et al., 1989) and type IV collagen (Ingber and Folkman, 1989 ) among others, directly induce the formation of capillary-like structures (CLS) from endothelial cells. In several ways tumour cells themselves can also promote angiogenesis, e.g. by secretion of angiogenic factors, protease activation or macrophage stimulation (Folkman and Shing, 1992) .
In vivo models, such as the chorioallantoic membrane assay or the rabbit cornea implant technique, are widely used for studying angiogenesis. These, however, do not permit evaluation of whether an angiogenic factor or an antiangiogenic molecule is acting directly on endothelial cells or indirectly via neighbouring cells, such as inflammatory cells and/or fibroblasts. Experimental approaches that reproduce the tumour-induced angiogenic process in vitro will help to study the molecular mechanisms involved in the interaction between tumour cells and endothelial cells during angiogenesis. Since the first description of maintenance of longterm cultures of capillary endothelial cells by addition of tumour cell conditioned medium (CM) (Folkman et al., 1979) , several in vitro angiogenesis assays have been described (reviewed in Auerbach et al., 1991) . These assays, such as the capillary formation within collagen or gelatin gels (Montesano and Orci, 1985; Pepper et al., 1992) , or the migration of endothelial cells in the silicon template compartmentalisation technique (Augustin-Voss and Pauli, 1992) , permit the analysis of the effect of angiogenic factors or tumour cell CM on individual angiogenic steps.
We have developed a modified chemotaxis chamber assay that allows simultaneous study of the different steps of the In vitro tumour-induced angiogenesis assay Polyvinylpyrrolidone-free polycarbonate filter Transwell inserts (6.5 mm diameter) with 8 tLm pores (Costar, Cambridge, MA, USA) were used for the assay. Matrigel (50 iLl from a 250 jg ml1 dilution in cold PBS) was applied to the upper surface of each filter and dried at room temperature under a hood. The underside of the filter was then coated with type I collagen (50 Ll from a 250 Lg ml-' dilution in 0.02 M acetic acid); in some experiments Matrigel (50 gl from a 750 jig ml-' dilution in cold PBS) was used instead of type I collagen. Tumour cell CM (600 1lI) was added to the lower chamber. Approximately 105 BAE cells (100 gl) were seeded in the upper chamber in DMEM supplemented with 0.2% bovine serum albumin. After incubation for 72 h at 37°C in a 5% carbon dioxide atmosphere, cells on the upper side of the filter were removed with cotton swabs. Filters were then stained with haematoxylin-eosin or with a Giemsa-modified staining method. The formation of CLS was assessed under the microscope and compared with controls having nonconditioned culture medium in the lower chamber.
Results

Tumour cell-inducedformation of CLS in BAE cells
In order to study whether tumour cell CM could induce the formation of CLS in BAE cells, these were added to the upper compartment of Transwell cell culture chambers, and CM from either B16FO or B16F1O cells, murine melanoma cells with different metastatic capacity (Fidler, 1973) , was added to the lower chamber; the filters of the Transwell inserts had been previously coated with Matrigel on the upper side and with type I collagen on the lower side ( Figure   1 ). The amount of Matrigel (12.5 fig) was sufficient to create a basement membrane-like barrier but was unable to induce the formation of CLS by BAE cells (data not shown). When CM from the highly metastatic B16F1O cell line was present in the lower well, within 72 h BAE cells degraded Matrigel, migrated through the filter pores and differentiated into CLS on the type I collagen coating (Figure 2a ). This CLS formation could also be observed using CM from the human metastatic breast adenocarcinoma cell line MDA-MB-23 1 (data not shown). In contrast, when CM of the less invasive Bl6FO cell line was used, no CLS were fonned on type I collagen ( Figure 2b ). However, when the lower coating of the filters contained Matrigel (37.5 gig) instead of type I collagen, no differences were observed between B16FlO (data not shown) and B16FO CM (Figure 2c ) and CLS were formed in both cases. Formation of CLS on type I collagen or Matrigel required in any case the presence of tumour cell CM, since few BAE cells migrated through the Matrigel layer and no differentiation was observed when non-conditioned culture medium was added to the lower compartment of the chamber (data not shown). Figure 3 Effect of an anti-bFGF antibody (a), an anti-laminin antibody (b and c) and suramin (d-f) on the formation of CLS on type I collagen by BAE cells in response to B16F1O CM. CLS formation was studied using the tumour-induced angiogenesis assay. Formation of CLS was abolished when an anti-bFGF antibody was added to the lower chamber (a). An anti-laminin antibody partially inhibited the formation of CLS when added to the upper chamber (b), but it had no effect when added to the lower chamber (c bFGF-inducedformation of CLS To evaluate whether bFGF, one of the most potent angiogenic factors known, is responsible for the angiogenic effect exerted by B16F10 CM, a neutralising anti-bFGF antibody (100 sgml-') was added together with the tumour cell CM; in this case the formation of CLS was abolished ( Figure 3a) . Moreover, capillary formation was induced on type I collagen when B16F10 CM was replaced by 10ngml-l bFGF (Figure 2d ).
Laminin-inducedformation of CLS
Laminin is one of the major constituents of Matrigel. To evaluate the role of this basement membrane protein in our in vitro tumour-induced angiogenesis model, in a separate set of experiments an anti-laminin antibody (100ilgml-') was added to the upper chamber, thus coming into contact with the Matrigel coating the filter. A reduction in the formation of CLS on type I collagen was observed (Figure 3b ) when compared to conditions without antibody (Figure 2a) . Moreover, addition of the anti-laminin antibody to the lower chamber, and thus in contact with the type I collagen coating the underside of the filter, had no effect on the formation of CLS by BAE cells (Figure 3c ).
Inhibition of the formation of CLS by suramin
The effect of the anti-angiogenic and anti-tumorigenic agent suramin was evaluated in our model system. Addition of non-toxic concentrations of suramin (10 and 1OO1M) to the lower chamber throughout the incubation period resulted in a marked dose-dependent effect, preventing endothelial cells from migrating and differentiating on type I collagen in response to B16F10 CM (Figure 3d and e). This inhibitory effect was not noticeable when suramin was added to the upper compartment of the Transwell cell culture chambers (Figure 3f) . A summary of the results is shown in Table I .
Discussion
Long-term cultures of capillary endothelial cells were firstly obtained by co-culture with tumour cell CM, thereby suggesting that tumour cells produce growth factors necessary for endothelial cell proliferation (Folkman et al., 1979) . Later, taking advantage of this fact, in vitro assays specific for single steps of the angiogenic process (migration, invasion, differentiation, proliferation of endothelial cells) were developed and were applied to study the regulatory mechanisms of angiogenesis and to screen for inhibitors (Auerbach et al., 1991 (Laterra and Goldstein, 1991) . A model system for tumour angiogenesis, based on the co-culture of tumour cell lines with endothelial cells in Transwell cell culture chambers, has recently been described. Using this co-culture system, tubular morphogenesis by human omentum microvascular endothelial cells in type I collagen gels was shown to be induced by transforming growth factor alpha (TGF-x)-producing oesophageal tumour cells or keratinocytes . BAE cells also form capillary structures in type I collagen when co-cultured with human glioma cell lines (Abe et al., 1993) ; in this case a direct correlation between tubulogenesis of BAE cells and bFGF mRNA levels in glioma cells was demonstrated. These findings support the hypothesis that tumour cells directly control not only the proliferation and invasion steps, but also the differentiation of endothelial cells during tumour-induced angiogenesis.
In order to develop a system able to reproduce simultaneously the overall angiogenic process, i.e. tumour-induced endothelial cell invasion and differentiation, we modified the chemotaxis chamber assay (Albini et al., 1987) in such a way that tumour cell CM induces the degradation of a Matrigel barrier by endothelial cells, their migration through it and their subsequent differentiation into CLS on a type I collagen layer. Although our tumour-induced angiogenesis assay shows homology to the co-culture system described by Abe et al. (1993) , there is a substantial difference between the models. In Abe's model, BAE cells seeded on a type I collagen gel migrate into it and differentiate into capillary structures; this tubulogenesis inside the gel requires a proteolytic degradation of type I collagen involving the activation of latent collagenase by tissue-type plasminogen activator (Sato et al., 1993 ). In our model system, type I collagen degradation takes place at the lower site of the filter, but an additional invasion step needs to take place in the Matrigel coating the upper side of the Transwell inserts. This Matrigel coating mimics more closely the in vivo situation in which endothelial cells have to degrade the basement membrane, whereas the type I collagen coating of the underside of the filter creates an environment similar to the interstitial matrix of the surrounding connective tissue, appropriate for the endothelial cells to organise into capillary structures. In summary, in our tumour-induced angiogenesis model, formation of CLS by BAE cells requires not only the activation of latent collagenases, but also the activation of type IV collagenases and other matrix metalloproteinases required for the degradation of Matrigel constituents.
In our model system BAE cells formed CLS on type I collagen in the presence of CM from the highly metastatic melanoma cell line B16FIO (Figure 2a ), but CLS formation did not take place when CM from the less invasive B16FO cell line was used (Figure 2b ). It is possible that B16FO cells do not produce sufficient amounts of angiogenic factors to induce the migration and differentiation of BAE cells, in contrast to B16F1O cells. Nevertheless, the possibility that B16FO cells produce TGF-P or other factors antagonising the effects of bFGF cannot be ruled out.
Formation of CLS could be blocked by anti-bFGF antibodies (Figure 3a) , suggesting a role for this angiogenic factor in the tumour-dependent induction of angiogenesis shown in our assay, although other factors can be involved as well. The lack of signal sequences in the bFGF gene argues against its secretion via classical mechanisms; however, its externalisation and release into the culture medium by novel mechanisms has been proposed (Mignatti and Rifkin, 1991) . The blocking of the effects of Bl6F0 CM by anti-bFGF antibody in our assay could therefore be explained if bFGF was released by such yet undefined mechanisms. A similar effect of anti-bFGF antibodies on the conditioned media of glioma cell lines has been described (Abe et al., 1993) .
When Matrigel is used instead of type I collagen for coating the lower side of the filters, CLS formation is induced even in the presence of B16FO CM (Figure 2c ), suggesting that a Matrigel constituent (probably bFGF) is triggering the migration and differentiation of BAE cells; nevertheless, the presence of a chemoattractant factor (either bFGF or others) in the tumour cell CM in the lower chamber is an essential requirement for our assay since neither migration nor differentiation of BAE cells occurs when non-conditioned culture medium is used.
Laminin and other basement membrane components have been described as modulators of angiogenesis in vitro (Grant et al., 1989; Ingber and Folkman, 1989) . In our tumourinduced angiogenesis model anti-laminin antibodies did not completely block the formation of CLS but reduced their number significantly (Figure 3b) . This is probably due to an inhibition of the attachment of BAE cells to laminin and the subsequent laminin-induced secretion of matrix metalloproteases (Turpeenniemi-Hujanen et al., 1986) , thereby blocking the migration and invasion of BAE cells through the Matrigel layer. The incomplete inhibition of CLS formation by anti-laminin antibodies in our assay could mean that other Matrigel components (probably type IV collagen, among others) are also involved in these events.
In order to validate this assay as a tool for studying tumour-induced angiogenesis, and especially for testing inhibitors, we evaluated the effect of suramin as a potential inhibitor. The mechanism of the anti-angiogenic activity of suramin is not completely understood, but the interaction of suramin with heparin-binding growth factors, such as bFGF, has been reported (Stein, 1989) , as well as the in vitro inhibition of the binding of several growth factors (such as bFGF, EGF, insulin-like growth factor I and platelet-derived growth factor) to their cell-surface receptors on endothelial cells. Moreover, suramin has been recenlty reported to inhibit each of the key control points of angiogenesis: endothelial cell migration, proliferation and production of proteases (Takano et al., 1994) . In our in vitro model, suramin, when added to the lower chamber, inhibited in a dose-dependent manner CLS formation by BAE cells on type I collagen ( Figure 3d and e); this is probably due to binding to bFGF present in B16F1O CM, thereby neutralising its biological activity. This inhibition of tubular morphogenesis by suramin was much lower when the drug was added to the upper compartment (Figure 3f ) than when it was added to the lower compartment of the Transwell cell culture chamber. This differential effect of suramin could be the result of its binding to heparan sulphate proteoglycans, one of the major components of Matrigel, thereby sequestering the drug and reducing its effective concentration; in this way, the ability of suramin to interact with growth factor receptors on endothelial cells and to diffuse through the filter, blocking bFGF in the lower chamber, would be greatly reduced.
In conclusion, in this in vitro model system we are able to study in combination the different steps that could be assayed separately with other previously described in vitro angiogenesis assays, i.e. basement membrane degradation (Murata et al., 1991) , endothelial cell migration towards angiogenic factors (Augustin-Voss et al., 1992) or capillary formation within three-dimensional collagen gels (Pepper et al., 1992; Abe et al., 1993) . This system reflects more closely the in vivo situation, and therefore we think that our tumourinduced angiogenesis model represents a valuable tool for the study of molecular interactions during the angiogenic process.
